Fine Tears 10 Ml Tablets (Rebamipide 20 mg (2% w/v)): Clinical Profile, Uses, Dosage, and Safety

Fine Tears 10 Ml Tablets is a prescription product containing Rebamipide 20 mg (2% w/v). It is used in clinically selected treatment pathways and should be used only under professional supervision. This page summarizes core product facts to support informed discussions with licensed healthcare professionals.

Safe use depends on diagnosis, formulation, route, dose, and duration. For this reason, the sections below provide a structured profile aligned with clinical documentation standards for pharmaceutical education and patient counseling.

Introduction

Fine Tears 10 Ml Tablets is a ophthalmic solution manufactured by Cipla Limited. It is positioned within the prescription pharmaceutical class and prescribed for condition-specific clinical goals. Treatment planning should always follow clinician judgment and local labeling.

Patients should verify product identity, strength, and route every time a medicine is dispensed. Similar brand names may represent different ingredients, and substitutions require clinician or pharmacist confirmation.

1. Product Overview / Clinical Profile

• Brand Name: Fine Tears 10 Ml Tablets
• Active Ingredient: Rebamipide 20 mg (2% w/v)
• Manufacturer: Cipla Limited
• Dosage Form: ophthalmic solution
• Therapeutic Category: prescription pharmaceutical

2. Mechanism of Action (MOA)

Fine Tears 10 Ml Tablets works through the pharmacology of Rebamipide 20 mg (2% w/v), with clinical effects determined by therapeutic class, dose, route, and patient-specific factors.

Mechanistic understanding helps explain prescribing rationale, expected response timelines, and monitoring requirements. For antimicrobials, susceptibility patterns and resistance risk are central. For chronic therapies, adherence and follow-up trends are key determinants of outcomes.

MOA should always be interpreted in context: pharmacology defines potential effect, but real-world response depends on diagnosis quality, adherence, interacting medicines, and patient-specific comorbidity burden.

3. Therapeutic Indications

Fine Tears 10 Ml Tablets is typically used for condition-specific use under physician supervision. Final indication should match approved labeling, clinician judgment, and patient-specific risk profile.

• Use only for the indication selected by a licensed prescriber.
• Avoid self-initiating or extending treatment duration without clinical review.
• Reassessment is needed if expected improvement does not occur within the expected clinical window.

Clinical teams may adjust treatment based on severity, prior therapy exposure, interaction profile, and objective response monitoring. The aim is benefit with minimized avoidable risk.

4. Dosage and Administration

General dosing guidance: 10 ml tablets, or as directed by the prescriber.

Exact schedules vary by diagnosis and patient profile. Prescribed instructions on timing, route, duration, and technique should be followed precisely.

• Use exactly as directed by the prescriber.
• Do not skip doses or double up missed doses unless advised.
• If ophthalmic, avoid touching the dropper or tube tip to any surface.
• If injectable, follow sterile handling and storage requirements.
• Ask the clinician for written missed-dose guidance at initiation.

Administration quality materially affects outcomes. Correct timing, route, and storage are often as important as selecting the correct medicine class.

5. Safety Profile and Precautions

Adverse effect profiles vary by active ingredient and class. Patients should review contraindications, allergy history, organ-function concerns, and interaction risks before first use. Persistent, severe, or unexpected symptoms require prompt medical review.

Key precautions include adherence to prescribed duration, avoiding unsupervised dose escalation, and reporting poor response early. For ophthalmic products, hygiene and contamination control are critical. For systemic agents, periodic laboratory monitoring may be required in higher-risk patients.

Immediately seek urgent care for severe hypersensitivity, breathing difficulty, progressive swelling, sudden vision changes, chest symptoms, or other acute deterioration.

Storage and Handling

Store according to official product labeling. Keep medicines in original packaging, away from heat and moisture, and out of reach of children. Ophthalmic products should remain capped and contamination-free; injectables may require strict temperature control.

Discard expired or compromised products. If a container appears damaged or contaminated, defer use until a pharmacist or clinician confirms suitability.

Clinical Follow-up and Counseling Points

Follow-up should assess therapeutic response, tolerance, and adherence. Patients should keep an updated medication list and disclose non-prescription product use to avoid interaction risks. This page is educational and does not replace individualized diagnosis or treatment planning.

Where relevant, clinicians may align treatment with antimicrobial stewardship, chronic disease protocols, and specialty pathways to preserve long-term efficacy and reduce avoidable adverse outcomes.

Medication counseling should include practical handling steps, what to do for missed doses, red-flag side effects, and when immediate escalation is required. In chronic conditions, continuity of care and routine review visits are essential for dose adjustments and long-term risk management.

Caregivers and patients should also be advised to avoid sharing medicines, avoid unsupervised therapy extension, and confirm refill appropriateness when symptoms recur. Recurrence may represent a different diagnosis and require reassessment rather than automatic repeat use.